RET and non-small cell lung carcinoma: A total of 105 RET fusion NSCLC patients enrolled in the phase 1/2 LIBRETTO - 001 trial received the Selpercatinib treatment had promising ORR(64%) and mDoR(17 months), and the mPFS of these patients was 16 months (16–18) (Table 1).